Abcam and EpiCypher have partnered to set a higher standard for antibody validation in CUT&RUN. By uniting Abcam’s deep recombinant antibody expertise with EpiCypher’s advanced chromatin profiling innovation, this collaboration delivers robust CUT&RUN antibodies validated to meet the demands of modern gene regulation research; where specificity, reproducibility, and biological accuracy define experimental success.

Why this partnership matters to you – the researcher
This collaboration was designed to empower researchers to generate higher confidence data, uncover new regulatory mechanisms, and move more quickly from hypothesis to discovery. Our approach to advance the science involved:

• Best-in-class antibodies for reagents you can trust
  • Recombinant, sequence-defined RabMAb^® monoclonals
  • Engineered for specificity and sensitivity
  • Batch-to-batch consistency for reproducible research
  • Widely cited and trusted in high-impact publications
• Expert CUT&RUN assessment using a more rigorous validation standard
  • Data generated and analyzed using the industry leading CUTANA™ CUT&RUN platform
  • Multiple clones screened to identify biologically consistent top performers
  • Chromatin-state controls included to confirm profiles reflect target biology
  • Robust signal-to-noise with enrichment at known target loci
  • Genome-wide benchmarking rather than single locus validation
  • Gold standard knockout validation for select targets to confirm specificity
• Focused on the targets that matter for studying gene regulatory pathways
  • Lineage-defining transcription factors (e.g. NOTCH1, FOXO3, ELK1)
  • Signal-activated transcriptional effectors (e.g. SMAD2/3, STAT1)
  • Growth and metabolic regulators (e.g. MYC, mTOR)
  • Chromatin writers, readers, and erasers (e.g. EHMT2/G9a, BRD9, HDAC2)

The result is a curated set of RabMab^® monoclonal antibodies validated directly within the CUTANA™ CUT&RUN ecosystem.  Shop Abcam antibodies validated for CUT&RUN: